You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Bispecific T cell receptor fusion protein

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumor, Advanced Breast Cancer, Advanced Gastric Cancer Trial in Boston, Dallas, Fairfax (IMM2902)

Recruiting
  • Advanced Solid Tumor
  • +2 more
  • Boston, Massachusetts
  • +2 more
Jul 21, 2022

Advanced Solid Tumor Trial in Bethesda, Boston (STAR0602)

Recruiting
  • Advanced Solid Tumor
  • Bethesda, Maryland
  • +1 more
Jan 6, 2023

Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited Trial in Zhengzhou (ThisCART19A, Fludarabine Pill, Cyclophosphamide)

Not yet recruiting
  • Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
  • Zhengzhou, Henan, China
    Henan cancer hospital
Nov 28, 2022

Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in United States (IMPT-314)

Not yet recruiting
  • Relapsed Non-Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Los Angeles, California
  • +3 more
Apr 12, 2023

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Trial in Tianjin (CD19-CD22 CAR-T cells)

Active, not recruiting
  • Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
  • CD19-CD22 CAR-T cells
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Aug 2, 2022

Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

Recruiting
  • Relapsed Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Nivolumab
  • Pembrolizumab
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jul 22, 2022

Prostate Specific Antigens, Prostate Tumors Trial run by the National Cancer Institute (NCI) (TARP peptide vaccine, TARP

Completed
Has Results
  • Prostate Specific Antigens
  • Prostate Neoplasms
  • T-cell receptor alternate reading frame protein (TARP) peptide vaccine
  • T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 15, 2022

Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between

Not yet recruiting
  • Recurrent ALK Positive Large B-Cell Lymphoma
  • +28 more
  • Biospecimen Collection
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Aug 17, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Tumor Trial in

Suspended
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
May 23, 2022

Multiple Myeloma Trial in New York (Infusion of MCARH109 T cells)

Active, not recruiting
  • Multiple Myeloma
  • Infusion of MCARH109 T cells
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 5, 2022

Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Los Angeles (procedure, drug, other)

Not yet recruiting
  • Recurrent Multiple Myeloma
  • Refractory Multiple Myeloma
  • Bone Marrow Aspiration
  • +10 more
  • Los Angeles, California
    Melanie Ayala Ceja
Jul 10, 2023

Advanced NSCLC Trial in China (KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein

Enrolling by invitation
  • Advanced Non-small Cell Lung Cancer
  • KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)
  • Axitinib
  • Hefei, Anhui, China
  • +5 more
Oct 26, 2022

Malignant Melanoma Trial in United Kingdom, United States (IMCgp100)

Completed
Has Results
  • Malignant Melanoma
  • Los Angeles, California
  • +8 more
Jul 1, 2020

Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult Trial in Germany (IMA402 (Phase Ia), IMA402 (Phase Ib), IMA402 (Phase

Not yet recruiting
  • Refractory Cancer
  • +3 more
  • IMA402 (Phase Ia)
  • +2 more
  • Heidelberg, Baden-Wuerttemberg, Germany
  • +12 more
Jul 14, 2023

Leukemia, Lymphoma Trial in Sanhe (anti-CD19 anti-CD20 Bispecific CAR-T)

Not yet recruiting
  • Leukemia
  • Lymphoma
  • anti-CD19 anti-CD20 Bispecific CAR-T
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Jan 19, 2021

Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute Adult Trial in Singapore (CAR

Recruiting
  • Lymphoblastic Leukemia, Acute, Childhood
  • +6 more
  • CAR T-cell therapy
  • Singapore, Singapore
    Allen Yeoh Eng Juh
Sep 7, 2021

Sarcoma, HER-2 Protein Overexpression Trial in Houston (cells, Pembrolizumab Injectable Product, Nivolumab Injectable Product)

Recruiting
  • Sarcoma
  • HER-2 Protein Overexpression
  • cells
  • +3 more
  • Houston, Texas
    Texas Children's Hospital
Dec 8, 2021

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein

Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +7 more
  • Blinatumomab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 31, 2022

DLBCL, Not Otherwise Specified, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial in Seattle

Terminated
Has Results
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • +5 more
  • Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 1, 2022

Select Advanced Solid Tumors Trial in Canada, United Kingdom, United States (IMCnyeso)

Terminated
Has Results
  • Select Advanced Solid Tumors
  • Aurora, Colorado
  • +11 more
Mar 9, 2022

B-ALL Trial in Moscow (CD19/CD22 CAR-T)

Recruiting
  • B-ALL
  • CD19/CD22 CAR-T
  • Moscow, Russian Federation
    Federal Research Institute of Pediatric Hematology, Oncology and
Jul 23, 2021

Advanced Melanoma Trial (Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice)

Not yet recruiting
  • Advanced Melanoma
  • (no location specified)
Sep 19, 2022

Prostatic Tumors, Prostate Cancer Trial run by the NCI (Autologus elutriated monocyte vaccine, Multi-epitope (ME) T-cell

Terminated
Has Results
  • Prostatic Neoplasms
  • Prostate Cancer
  • Autologus elutriated monocyte placebo vaccine
  • Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Mar 10, 2022

Uveal Melanoma Trial (Tebentafusp)

Available
  • Uveal Melanoma
  • (no location specified)
Jan 5, 2022

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells,

Terminated
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +10 more
  • Los Angeles, California
    USC / Norris Comprehensive Cancer Center
Nov 17, 2021